These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11512051)

  • 1. The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.
    Roth BL; Ernsberger P; Steinberg SA; Rao S; Rauser L; Savage J; Hufeisen S; Berridge MS; Muzic RF
    Psychopharmacology (Berl); 2001 Aug; 157(1):111-4. PubMed ID: 11512051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging of myocardial beta-adrenergic receptors with fluorocarazolol: lack of interference by endogenous catecholamines.
    Salinas C; Muzic RF; Berridge M; Ernsberger P
    J Cardiovasc Pharmacol; 2005 Aug; 46(2):222-31. PubMed ID: 16044035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, binding properties, and 18F labeling of fluorocarazolol, a high-affinity beta-adrenergic receptor antagonist.
    Zheng L; Berridge MS; Ernsberger P
    J Med Chem; 1994 Sep; 37(20):3219-30. PubMed ID: 7932549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of the beta adrenergic receptor antagonist bucindolol with serotonergic receptors.
    Watts SW; Fink GD; Silver PJ; Cushing DJ
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):29-36. PubMed ID: 10630730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial and pulmonary uptake of S-1'-[18F]fluorocarazolol in intact rats reflects radioligand binding to beta-adrenoceptors.
    Van Waarde A; Elsinga PH; Brodde OE; Visser GM; Vaalburg W
    Eur J Pharmacol; 1995 Jan; 272(2-3):159-68. PubMed ID: 7713160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
    Newman-Tancredi A; Nicolas JP; Audinot V; Gavaudan S; Verrièle L; Touzard M; Chaput C; Richard N; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):197-206. PubMed ID: 9750005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of S-1'-[18F]fluorocarazolol for in vivo imaging and quantification of cerebral beta-adrenoceptors.
    Doze P; Van Waarde A; Elsinga PH; Van-Loenen Weemaes AM; Willemsen AT; Vaalburg W
    Eur J Pharmacol; 1998 Jul; 353(2-3):215-26. PubMed ID: 9726651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of (S)-[18F]-fluoroethylcarazolol for in vivo beta-adrenoceptor imaging in the brain.
    Doze P; van Waarde A; Tewson TJ; Vaalburg W; Elsinga PH
    Neurochem Int; 2002 Jul; 41(1):17-27. PubMed ID: 11918968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
    Newman-Tancredi A; Verrièle L; Chaput C; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Mar; 357(3):205-17. PubMed ID: 9550290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
    Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging beta-adrenoceptors in the human brain with (S)-1'-[18F]fluorocarazolol.
    van Waarde A; Visser TJ; Elsinga PH; de Jong B; van der Mark TW; Kraan J; Ensing K; Pruim J; Willemsen AT; Brodde OE; Visser GM; Paans AM; Vaalburg W
    J Nucl Med; 1997 Jun; 38(6):934-9. PubMed ID: 9189145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (S,S)- and (S,R)-1'-[18F]fluorocarazolol, ligands for the visualization of pulmonary beta-adrenergic receptors with PET.
    Elsinga PH; Vos MG; van Waarde A; Braker AH; de Groot TJ; Anthonio RL; Weemaes AA; Brodde OE; Visser GM; Vaalburg W
    Nucl Med Biol; 1996 Feb; 23(2):159-67. PubMed ID: 8868289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes.
    Innis RB; Corrēa FM; Synder SH
    Life Sci; 1979 Jun; 24(24):2255-64. PubMed ID: 41147
    [No Abstract]   [Full Text] [Related]  

  • 16. 2-H- and 2-acyl-9- [omega-[4-(2-methoxyphenyl)piperazinyl]-alkyl]-1,2,3,4-tetrahydro-beta-carbolines as ligands of 5-HT1A and 5-HT2A receptors.
    Boksa J; Mokrosz MJ; Charakchieva-Minol S; Tatarczyńska E; Kłodzińska A; Wesołowska A; Misztal S
    Pol J Pharmacol; 2001; 53(5):501-8. PubMed ID: 11990069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
    Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCS-MPP (4-(2'-methoxy-phenyl)-1-[2'-(N-2"-pyridyl)-p-isothiocyanobenz amido]-ethyl-piperazine): a high affinity and irreversible 5-HT1A receptor ligand.
    Kung MP; Mu M; Zhuang ZP; Kung HF
    Life Sci; 1996; 58(3):177-86. PubMed ID: 9499158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iterative optimal design of PET experiments for estimating beta-adrenergic receptor concentration.
    Muzic RF; Saidel GM; Zhu N; Nelson AD; Zheng L; Berridge MS
    Med Biol Eng Comput; 2000 Nov; 38(6):593-602. PubMed ID: 11217875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two putatively selective radioligands for labeling central nervous system beta-adrenergic receptors: inadequacy of [3H]dihydroalprenolol.
    Riva MA; Creese I
    Mol Pharmacol; 1989 Jul; 36(1):201-10. PubMed ID: 2546050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.